$17.64
-1.07%
N/A-$0.19
헬스케어
의료 - 기기
NASDAQ
활발히 거래 중
NovoCure Limited는 종양 치료 분야의 기업으로, 미국, 독일, 프랑스, 일본, 그레이터 차이나 및 전 세계에서 고형 종양 암의 치료를 위한 종양 치료 ...
NovoCure Limited는 종양 치료 분야의 기업으로, 미국, 독일, 프랑스, 일본, 그레이터 차이나 및 전 세계에서 고형 종양 암의 치료를 위한 종양 치료 ...
Optune Gio is a non-invasive, portable device that creates an electric field within the brain to disrupt the rapid division of cancer cells in glioblastoma patients. It is intended to be used in conjunction with standard-of-care treatments, providing a continuous, home-based therapeutic option to extend patient survival.
가격대: Not publicly disclosed (typically managed through medical insurance and healthcare provider channels)
페인 포인트: High mortality rates of glioblastoma, limitations of systemic chemotherapy, and the need for treatments that can be administered in a home setting.
솔루션: Disrupts cancer cell mitosis via TTFields, potentially extending overall survival and improving quality of life by allowing patients to remain active and home-bound during treatment.
대상 사용자: Healthcare providers (oncologists, neuro-oncologists) and patients diagnosed with glioblastoma.
Optune Lua is designed to deliver TTFields to the chest area to treat malignant pleural mesothelioma. The device works by disrupting the cell division of mesothelioma cancer cells when used alongside standard pemetrexed and platinum-based chemotherapy.
가격대: Not publicly disclosed
페인 포인트: Limited treatment options for aggressive thoracic cancers and the toxicity associated with traditional chemotherapy regimens.
솔루션: Provides a non-systemic, non-invasive treatment modality that can be used concomitantly with chemotherapy to enhance treatment outcomes.
대상 사용자: Oncologists and patients diagnosed with malignant pleural mesothelioma.
Optune Pax is a device approved by the FDA for the treatment of locally advanced pancreatic cancer when used in conjunction with gemcitabine and nab-paclitaxel. It leverages the company's proprietary TTFields technology to provide a new therapeutic option for this challenging indication.
가격대: Not publicly disclosed
페인 포인트: Severe lack of new treatment options for pancreatic cancer patients and the aggressive, hard-to-treat nature of the disease.
솔루션: Offers a breakthrough, FDA-approved therapeutic approach that disrupts cancer cell division in the pancreas when used alongside standard chemotherapy.
대상 사용자: Gastroenterology-oncologists and patients diagnosed with locally advanced pancreatic cancer.